These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 32636098)

  • 1. DNA Repair and Prostate Cancer: A Field Ripe for Harvest.
    Bryce AH; Sartor O; de Bono J
    Eur Urol; 2020 Oct; 78(4):486-488. PubMed ID: 32636098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review.
    Ratta R; Guida A; Scotté F; Neuzillet Y; Teillet AB; Lebret T; Beuzeboc P
    Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):549-560. PubMed ID: 32367009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer.
    Flippot R; Patrikidou A; Aldea M; Colomba E; Lavaud P; Albigès L; Naoun N; Blanchard P; Terlizzi M; Garcia C; Bernard-Tessier A; Fuerea A; Di Palma M; Escudier B; Loriot Y; Baciarello G; Fizazi K
    Drugs; 2022 May; 82(7):719-733. PubMed ID: 35511402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The promising PARP inhibitors in ovarian cancer therapy: From Olaparib to others.
    Chen Y; Du H
    Biomed Pharmacother; 2018 Mar; 99():552-560. PubMed ID: 29895102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poly(ADP-ribose) polymerase inhibitors in prostate cancer: a cornerstone in precision oncology.
    Ziadeh T; Kourie HR
    Pharmacogenomics; 2021 Dec; 22(18):1237-1250. PubMed ID: 34729995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Veliparib: a new therapeutic option in ovarian cancer?
    Ghisoni E; Giannone G; Tuninetti V; Genta S; Scotto G; Aglietta M; Sangiolo D; Mittica G; Valabrega G
    Future Oncol; 2019 Jun; 15(17):1975-1987. PubMed ID: 31074636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Niraparib Shows Superior Tissue Distribution and Efficacy in a Prostate Cancer Bone Metastasis Model Compared with Other PARP Inhibitors.
    Snyder LA; Damle R; Patel S; Bohrer J; Fiorella A; Driscoll J; Hawkins R; Stratton CF; Manning CD; Tatikola K; Tryputsen V; Packman K; Mamidi RNVS
    Mol Cancer Ther; 2022 Jul; 21(7):1115-1124. PubMed ID: 35499386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PARP Inhibition in Advanced Prostate Cancer.
    Fenton SE; Chalmers ZR; Hussain M
    Cancer J; 2021 Nov-Dec 01; 27(6):457-464. PubMed ID: 34904808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics.
    Gong J; Posadas E; Bhowmick N; Kim H; Daskivich T; Gupta A; Sandler H; Kamrava M; Zumsteg Z; Freedland S; Figlin R
    Oncology (Williston Park); 2021 Mar; 35(3):119-125. PubMed ID: 33818052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PARP inhibitors in prostate cancer: time to narrow patient selection?
    Markowski MC; Antonarakis ES
    Expert Rev Anticancer Ther; 2020 Jul; 20(7):523-526. PubMed ID: 32521178
    [No Abstract]   [Full Text] [Related]  

  • 11. The emerging role of PARP inhibitors in prostate cancer.
    Stellato M; Guadalupi V; Sepe P; Mennitto A; Claps M; Zattarin E; Verzoni E; Valdagni R; De Braud FG; Santini D; Tonini G; Procopio G
    Expert Rev Anticancer Ther; 2020 Aug; 20(8):715-726. PubMed ID: 32758032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
    Antonarakis ES; Gomella LG; Petrylak DP
    Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells.
    Yin L; Liu Y; Peng Y; Peng Y; Yu X; Gao Y; Yuan B; Zhu Q; Cao T; He L; Gong Z; Sun L; Fan X; Li X
    J Exp Clin Cancer Res; 2018 Jul; 37(1):153. PubMed ID: 30012171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defective DNA repair mechanisms in prostate cancer: impact of olaparib.
    De Felice F; Tombolini V; Marampon F; Musella A; Marchetti C
    Drug Des Devel Ther; 2017; 11():547-552. PubMed ID: 28280302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PARP inhibition in prostate cancer.
    Nientiedt C; Duensing A; Zschäbitz S; Jäger D; Hohenfellner M; Stenzinger A; Duensing S
    Genes Chromosomes Cancer; 2021 May; 60(5):344-351. PubMed ID: 33084183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond.
    Boussios S; Abson C; Moschetta M; Rassy E; Karathanasi A; Bhat T; Ghumman F; Sheriff M; Pavlidis N
    Drugs R D; 2020 Jun; 20(2):55-73. PubMed ID: 32215876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 5-WS of targeting DNA-damage repair (DDR) pathways in prostate cancer.
    Guida A; Mosillo C; Mammone G; Caserta C; Sirgiovanni G; Conteduca V; Bracarda S
    Cancer Treat Rev; 2024 Jul; 128():102766. PubMed ID: 38763054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies.
    Li Y; Liu CF; Rao GW
    Curr Med Chem; 2021; 28(8):1565-1584. PubMed ID: 32164505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status and progress in using radiolabelled PARP-1 inhibitors for imaging PARP-1 expression in tumours.
    Wang Q; Zhang J
    Eur J Med Chem; 2022 Nov; 242():114690. PubMed ID: 36041258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personalized medicine for metastatic prostate cancer: The paradigm of PARP inhibitors.
    Maiorano BA; Conteduca V; Catalano M; Antonuzzo L; Maiello E; De Giorgi U; Roviello G
    Crit Rev Oncol Hematol; 2023 Dec; 192():104157. PubMed ID: 37863403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.